Elysia 4-2A
Solution dedicated to quality control in laboratories for the production of Radio Pharmaceuticals (equipment / SW / services).
€8,400
total amount raised
This campaign has been closed
Market positioning
Be the number 1 specialist for radio-QC Lab:
• Larger products range (only products directly related to the radio-Pharmacy)
• Get Independent of competition and third party suppliers
• Get better control on production costs to increase margin
• Deliver Shareware to bind customers to our solution
• Better integration of radio-production and radio-QC (Gaia)
• Faster growth
• Larger installed base and more recurrent business
• Marketing strategies for existing customers (leasing, upgrades…)
• Get Independent of competition and third party suppliers
• Get better control on production costs to increase margin
• Deliver Shareware to bind customers to our solution
• Better integration of radio-production and radio-QC (Gaia)
• Faster growth
• Larger installed base and more recurrent business
• Marketing strategies for existing customers (leasing, upgrades…)
Market trends
Selon l’étude de marché « MarketsandMarkets » publiée en 2011 (Global Radiopharmaceuticals Market (PET/SPECT Imaging & Therapy) - Current Trends & Forecasts (2010-2015)), les revenus du marché global des RP étaient de 3,2 milliards de dollars en 2010 pour arriver à environ 4,7 milliards de dollars en 2017, avec une croissance annuelle moyenne de 8,1% (CAGR) entre 2010 et 2015.
Les applications pour le diagnostic représentent le plus grand segment, avec des revenus de 2,8 milliards de dollars en 2010 pour arriver à environ 4,2 milliards de dollars en 2017, avec une croissance annuelle moyenne de 8,4% entre 2010 et 2015.
Les applications thérapeutiques étaient de 376 millions de dollars en 2010 pour arriver à environ 490 millions de dollars en 2017, avec une croissance annuelle moyenne de 5,4% entre 2010 et 2015.
Les principales tendances identifiées dans la recherche documentaire sont les suivantes :
- une augmentation du scope de pathologies traitées par les RP (maladies d’Alzheimer et Parkinson) ;
- une diminution du prix moyen de ces substances (contrebalancée par une augmentation des quantités vendues) ;
- un renforcement des normes relatives à la production, la distribution et l’utilisation des RP (barrières à l’entrée) ;
- le développement des générateurs de petite dimension (exemple pour le gallium-68 ou le technetium-99) ;
- une réduction au niveau du remboursement des RP par les organismes de sécurité sociale au niveau national.
Hereunder a rapid PEST-ANALYSIS : · Political / Regulations: Political changes and regulations might impose stricter rules on quality control which would benefit to Elysia · Economic: Economical changes will not impact the business · Social: Aging population and new diseases increase the need for new technology and thus will benefit to Elysia · Technological: Technological product hence changes in technology will impact Elysia though Elysia is very versatile and can work with any new molecule, which is not the case of their competitors.
Competition
Direct competition: companies offering quality control solutions
- LabLogic (UK): LIMS PETra solution is one of the most important competing products, but this solution is sold at excessive prices.
- QC-One (Germany): has developed a software for synthesis companies and HPLC radio’s for quality controls - LAQC (Canada): provides software training, software support & customization to clinical laboratories and diagnostic companies.
- EC2- Software solutions (US): offers software products that help medical providers navigate the vast and complex regulations of the Nuclear Medicine industry.
Indirect competition:
- Home-made solutions and SAP pharma; - Providers of services, e.g. ORA (Optimized Radiochemical Applications), located in Belgium. It helps obtaining GMP certifications for the production of FDG (laboratory design, equipment qualification and process validation), obtaining authorisation to place the product on the market and establishing QC systems; - General management software solutions for nuclear medicine.
- LabLogic (UK): LIMS PETra solution is one of the most important competing products, but this solution is sold at excessive prices.
- QC-One (Germany): has developed a software for synthesis companies and HPLC radio’s for quality controls - LAQC (Canada): provides software training, software support & customization to clinical laboratories and diagnostic companies.
- EC2- Software solutions (US): offers software products that help medical providers navigate the vast and complex regulations of the Nuclear Medicine industry.
Indirect competition:
- Home-made solutions and SAP pharma; - Providers of services, e.g. ORA (Optimized Radiochemical Applications), located in Belgium. It helps obtaining GMP certifications for the production of FDG (laboratory design, equipment qualification and process validation), obtaining authorisation to place the product on the market and establishing QC systems; - General management software solutions for nuclear medicine.